By virtue of their capacity to bind the CRD of Gal-3, they interfere with its attachment to glycan-containing surfaces [111] and can inhibit the Gal-3 downstream signaling mechanisms that controls apoptosis and cell cycle in CRC cells as well as the activation of tumor-specific immune responses [112]. The gene discussed is LGALS3; the disease is colorectal carcinoma.